论文部分内容阅读
目的 :分析血必净注射液联合参附注射液对脓毒症的治疗价值。方法 :研究对象选取本院2013年9月至2015年8月收治的74例脓毒症患者,通过电脑随机的方式将患者分为实验组与参比组各37例。参比组患者严格按照脓毒症治疗指南的标准治疗;实验组患者在这一基础上给予血必净注射液联合参附注射液进行治疗。对两组患者血清指标结果与不良反应发生情况对比。结果 :实验组患者的红细胞沉降率、纤维蛋白原、血清降钙素原、巨噬细胞炎症蛋白等指标结果优于参比组,对比差异显著(P<0.05);两组患者不良反应均少见,且对治疗无不利影响,对比差异无统计学意义(P>0.05)。结论 :血必净注射液联合参附注射液对改善脓毒症各项指标具有较高的价值,且安全性高,值得推广。
Objective: To analyze the therapeutic value of Xuebijing injection and Shenfu injection on sepsis. Methods: Seventy-four patients with sepsis admitted from September 2013 to August 2015 in our hospital were randomly divided into experimental group (37 cases) and reference group (37 cases). Patients in the reference group were treated in strict accordance with the guidelines for the treatment of sepsis. The patients in the experimental group were given Xuebijing Injection and Shenfu Injection for treatment. The results of the two groups of patients with serum indicators of adverse reactions compared with the situation. Results: The results of erythrocyte sedimentation rate, fibrinogen, procalcitonin and macrophage inflammatory protein in experimental group were better than those in the reference group (P <0.05). Adverse reactions in both groups were rare , And no adverse effect on treatment, the difference was not statistically significant (P> 0.05). Conclusion: Xuebijing Injection and Shenfu Injection have high value for improving various indexes of sepsis, and they are safe and worthy of promotion.